Cost-effectiveness and cost-utility analysis of Haemate-P versus other von Willebrand disease treatments in Spain
In patients with severe vWD experiencing a high bleed rate, Haemate-P prophylaxis is a less costly and potentially more effective treatment strategy and Haemate-P is cost-saving among on-demand strategies.
Authors
- Stephan Linden (ORCID: https://orcid.org/0000-0002-2106-1799)
- Juan Eduardo Megías‐Vericat (ORCID: https://orcid.org/0000-0002-0369-5341)
- Songkai Yan (ORCID: https://orcid.org/0000-0002-1677-3839)
- Ginés Escolar (ORCID: https://orcid.org/0000-0002-6658-0381)
- Marco Panebianco
- Cheryl L. McDade (ORCID: https://orcid.org/0000-0002-6216-8955)
- Radovan Tomic
- Pablo Méndez (ORCID: https://orcid.org/0000-0001-9862-6818)
- Michele Wilson (ORCID: https://orcid.org/0000-0003-4390-4192)
- Laura Vidal Barrientos
Institutions
- Hospital Universitari i Politècnic La Fe (ES)
- CSL (United States) (US)
- Hospital Clínic de Barcelona (ES)
- RTI Health Solutions (US)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- CSL (Switzerland) (CH)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1080/13696998.2025.2474886
- Citations
- 1
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77